1. Home
  2. ENTX vs SHMD Comparison

ENTX vs SHMD Comparison

Compare ENTX & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SHMD
  • Stock Information
  • Founded
  • ENTX 2010
  • SHMD 1864
  • Country
  • ENTX Israel
  • SHMD Germany
  • Employees
  • ENTX N/A
  • SHMD N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SHMD
  • Sector
  • ENTX Health Care
  • SHMD
  • Exchange
  • ENTX Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • ENTX 90.2M
  • SHMD 86.1M
  • IPO Year
  • ENTX 2018
  • SHMD N/A
  • Fundamental
  • Price
  • ENTX $2.37
  • SHMD $2.50
  • Analyst Decision
  • ENTX Strong Buy
  • SHMD
  • Analyst Count
  • ENTX 1
  • SHMD 0
  • Target Price
  • ENTX $10.00
  • SHMD N/A
  • AVG Volume (30 Days)
  • ENTX 88.5K
  • SHMD 55.0K
  • Earning Date
  • ENTX 03-07-2025
  • SHMD 02-25-2025
  • Dividend Yield
  • ENTX N/A
  • SHMD N/A
  • EPS Growth
  • ENTX N/A
  • SHMD 1309.32
  • EPS
  • ENTX N/A
  • SHMD 1.07
  • Revenue
  • ENTX $99,000.00
  • SHMD $99,752,404.00
  • Revenue This Year
  • ENTX N/A
  • SHMD N/A
  • Revenue Next Year
  • ENTX N/A
  • SHMD N/A
  • P/E Ratio
  • ENTX N/A
  • SHMD $2.11
  • Revenue Growth
  • ENTX 607.14
  • SHMD N/A
  • 52 Week Low
  • ENTX $0.82
  • SHMD $1.86
  • 52 Week High
  • ENTX $3.35
  • SHMD $6.13
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 51.69
  • SHMD N/A
  • Support Level
  • ENTX $2.32
  • SHMD N/A
  • Resistance Level
  • ENTX $2.62
  • SHMD N/A
  • Average True Range (ATR)
  • ENTX 0.20
  • SHMD 0.00
  • MACD
  • ENTX -0.00
  • SHMD 0.00
  • Stochastic Oscillator
  • ENTX 59.68
  • SHMD 0.00

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: